A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses. READ MORE
Does First-Line Targeted Therapy Plus Immunotherapy Produce Durable Responses in ALK-Positive NSCLC?
A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses.
A recent survey highlighted the need for educational resources to go further in-depth into immunotherapy science and management strategies for treatment-related adverse events.
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
A recent study summarized the available evidence on adverse events associated with checkpoint inhibitors in patients with cancer and preexisting autoimmune disease.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network have collaborated for the first time to release new clinical guidelines for managing immunotherapy-related toxicities.
The International Association for the Study of Lung Cancer has launched a guideline for nurses and clinicians who are treating lung cancer with immunotherapy and encounter adverse events.
From January 25-27, the American Society of Clinical Oncology hosted its Clinical Immuno-Oncology Symposium in San Francisco, California. The meeting will highlight some of the largest updates in clinical and translational research in immuno-oncology and the implications for clinical care.